Diskusjon Triggere PortefĂžljer AksjonĂŠrlister

Nordic Nanovector - Fundamentale forhold 2019 (NANO)

Biotek
#6514

Bruker Costa State Street Bank? Hvordan vet du det?

#6515

Her er primĂŠrinnsiderene forresten:

https://www.oslobors.no/markedsaktivitet/#/details/NANO.OSE/insiders

1 Like
#6516

Jeg sa ikke at han bruker S.S. Det er meget interessant hvis han sÄ gjÞr.

#6517

Javel? Merkelig spekulasjon.

#6518

Helt Êrlig tipper jeg han er pÄ Credit Suisse

#6519

Det blir i hvert fall spennende Ă„ fĂžlge hva han foretar seg videre. Hans nye arbeidsgiver kan jo vĂŠre en potensiell investor i Nano?

" BB Pureos Bioventures is a newly venture capital franchise to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.
For Pureos, we have assembled a team of venture managers, biotech founders, scientists and big pharma & biotech executives, with long-standing experience in biologic drug development, company building and healthcare investing, and a wide-spanning network."

http://www.pureosbio.com/en/

1 Like
#6520

Er det noe som tilsier at det mÄ vÊre Costa, eller spekuleres det bare? Jeg er enig i at det er realtivt sannsynlig at det er han.

#6521

Ser ut som noen er redd for Zevalin. Det er det INGEN grunn til.
Betalutin har absolutt alle kort pÄ hÄnden vs Zevalin.
Begge har f.eks gammastrÄling som et biprodukt. GammastrÄlingen til Zevalin er nesten 10 ganger heftigere, om jeg husker rett. PÄ grensen til farlige nivÄer bÄde med hensyn til produksjon, logistikk, hÄndtering hos klinikere og for pasienten.
Halveringstiden (for kort) gjÞr ogsÄ Zevalin til annenrangs. Mesteparten av strÄlingen vil vÊre over fÞr medisinen fÄr «satt seg».
Dessuten retter den seg mot CD20 som mange har pÄpekt.

Edit. GammastrÄlingen er OVER 10 ganger sterkere.

At dette produktet er godkjent gjÞr at Betalutin nesten 100% sikkert blir godkjent. Det finnes ingen motargumenter, nÄr vi er bedre pÄ alt.

6 Likes
#6522

Du skal se det at Zevalin blir avhengig av forbehandling med Betalutin.

1 Like
#6523

Er dette positivt for Nordic Nanovector 
?

https://lymphomanewstoday.com/2018/09/25/nice-rejects-kymriah-treating-aggressive-dlbcl-england-national-health-service/?utm_medium=desktop-push-notification&utm_source=Notifications&utm_campaign=OneSignal

#6524

NANO har ikke offentliggjort noen data mot DLBCL enda, sÄ tror ikke det er noe Ä tenke pÄ enda.
CAR-T er kostbart og krevende, og sÄledes ikke ventet Ä spise opp for mye marked. Slik ble det guidet av LC i 2016 allerede om jeg husker rett, de vil nok likevel behandle en andel av markedet.
Siden CAR-T er en konkurrent for Archer-1, gir det kanskje et positivt hint den veien.

1 Like
#6525

Den Wiley-publikasjonen lenger opp med NANO-resultater pÄ, hvilken journal/konferanse var den fra?

#6527

Kanskje denne? Publisert tidligere i sommer. Innlegg fra diffish.
Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin’s lymphoma - Repetto‐Llamazares - 2018 - European Journal of Haematology - Wiley Online Library

https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13139

#6528

Hugoil
 som ungene mine sier: seriþst?

Regner med du klikket pÄ linken fÞr du spÞr andre om hjelp.

Hele siden du fÄr opp er fargelagt med logoen til hvilken journal artikkelen er hentet fra. I tillegg er det flere skriftlige henvisninger til denne, inludert linker.

47
Screen Shot 2018-09-30 at 22.07.47.png2124×696 326 KB

1 Like
#6529

Forresten, enklest Ă„ hente den her, fra Nanos egne hjemmesider. Her er PDF.
http://www.nordicnanovector.com/sites/default/files/Repetto-Llamazares_et_al-2018-European_Journal_of_Haematology.pdf

#6530

SerriĂžst!:slight_smile:
Ser dere en sammenheng mellom den og
https://helseforskning.etikkom.no/prosjekterirek/prosjektregister/prosjekt?p_document_id=1027580&p_parent_id=1047097&_ikbLanguageCode=n

1 Like
#6531

Hver mĂ„ned kĂ„rer jeg det jeg kaller Teksperterℱ for noen av de mest populĂŠre investeringene vĂ„re :slight_smile:

Det er de 3 medlemmene som har fĂ„tt flest likes pĂ„ innleggene sine de siste 90 dagene. Teksperterℱ fĂ„r ogsĂ„ en unikt merke pĂ„ profilen sin og et trofĂ©-ikon ved siden av navnet sitt. Du kan bli Tekspertℱ i flere aksjer/investeringer, og trofĂ©et vil bare vises i trĂ„der der du er Tekspertℱ.

Her er denne mĂ„nedens Teksperterℱ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @Fornybar (781 likes)
  1. @Savepig (433 likes)
  1. @anon21766851 (371 likes)

Resten av topp 10:

  1. @Inkognito666 (338 likes)

  2. @studenten86 (317 likes)

  3. @Nocturne (192 likes)

  4. @Oilimp (180 likes)

  5. @Hallakis (171 likes)

  6. @vegar_beider (130 likes)

  7. @koe (92 likes)

Gratulerer!

3 Likes
#6532

Nordic Nanovector: Abstracts of LYMRIT 37-01 Study with BetalutinÂź in NHL Patients and other Studies accepted for poster presentations at ASH

Oslo, Norway, 2 October 2018

Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin¼ (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (iNHL) has been accepted for a poster presentation at the 60th Annual Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018, San Diego, CA).

Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin¼) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month follow-up

Authors: A. Kolstad, et al.

The Company will also have two non-clinical posters: one presenting BetalutinÂź and one presenting the investigational anti-CD37 radioimmunoconjugate 212Pb-NNV003, which is under evaluation in a research collaboration between Nordic Nanovector and Orano Med (formerly AREVA Med).

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177Lu-lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma

Authors: G.R. RĂždland et al.

Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Authors: A. Saidi et al.

The abstracts will be published on 1 November 2018 at 09:00am Eastern time at http://www.hematology.org/Annual-Meeting/

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin¼, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin¼ in core markets. Further information can be found at www.nordicnanovector.com

 

Ekstern link: http://news.cision.com/nordic-nanovector/r/nordic-nanovector–abstracts-of-lymrit-37-01-study-with-betalutin–in-nhl-patients-and-other-studies,c2632896

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20181002.Cision.20181001:BIT:9496:0

4 Likes
#6533

Nordic Nanovector: Abstracts of LYMRIT 37-01 Study with BetalutinÂź in NHL Patients and other Studies accepted for poster presentations at AS

Oslo, Norway, 2 October 2018

Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting data from
the Phase 1/2a LYMRIT 37-01 study investigating BetalutinÂź (177Lu-lilotomab
satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s
lymphoma (iNHL) has been accepted for a poster presentation at the 60th Annual
Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018, San
Diego, CA).

Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan
(BetalutinÂź) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed
non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month follow-up

Authors: A. Kolstad, et al.

The Company will also have two non-clinical posters: one presenting BetalutinÂź
and one presenting the investigational anti-CD37 radioimmunoconjugate 212Pb
-NNV003, which is under evaluation in a research collaboration between Nordic
Nanovector and Orano Med (formerly AREVA Med).

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177Lu-lilotomab
Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma

Authors: G.R. RĂždland et al.

Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B
-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Authors: A. Saidi et al.

The abstracts will be published on 1 November 2018 at 09:00am Eastern time at
http://www.hematology.org/Annual-Meeting/

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
BetalutinÂź, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
BetalutinÂź in core markets. Further information can be found at
www.nordicnanovector

Ekstern link: http://www.newsweb.no/index.jsp?messageId=460508

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20181002.OBI.20181002S9

2 Likes
#6534

Yes! Dette burde bevege kurset litt!

Spesielt kult at de har fÄtt med to postere ogsÄ!

The Company will also have two non-clinical posters: one presenting BetalutinÂź
and one presenting the investigational anti-CD37 radioimmunoconjugate 212Pb
-NNV003, which is under evaluation in a research collaboration between Nordic
Nanovector and Orano Med (formerly AREVA Med).

2 Likes